DOI: https://doi.org/10.21203/rs.3.rs-63873/v1
Background: This study is to investigate the effects of miR-24 on expression of eNOS and Sp1, the proliferation, migration, and tube formation abilities of human umbilical vein endothelial cells (HUVECs).
Results: After transfection with miR-24 overexpression plasmid or anti-miR-24, miR-24 was successfully over-expressed or inhibited. Compared with the control group, the HUVEC proliferation and cell number in the miR-24 high expression group was significantly decreased. Moreover, for the miR-24 high expression group, the cell motility was slower, and the migrating cells were significantly decreased by 61.20%, with very few capillaries in the Matrigel assay. Furthermore, the mRNA and protein expression levels of eNOS were decreased by 44.44% and 47.00 %, respectively. Meanwhile, the mRNA and protein levels of Sp1 were significantly decreased by 34.88% and 68.00%, respectively. In the miR-24 interference group, the above indexes were decreased compared with control group, while significantly increased compared with the miR-24 high expression group, especially concerning the number of branches and the tube length. Moreover, the Sp-1 and eNOS mRNAs were found to be the direct targets of miR-24 by a luciferase reporter system.
Conclusion: Over-expression of miR-24 significantly suppresses cell proliferation, migration, and tube formation ability of HUVECs, via regulating eNOS expression. The transcription factor Sp1, a target of miR-24, might contribute to the eNOS expression regulation and the inhibiting effects on HUVECs.
In recent years, it has been found that several microRNAs (miRNAs or miRs) are involved in the regulation of proliferation, migration, and morphological changes of vascular endothelial cells, thus modulating the angiogenesis process. However, the abnormal expression of these miRNAs has also been shown to be related to the development of cardiovascular diseases (1, 2). Endothelial nitric oxide synthase (eNOS) is an endothelial tissue-specific gene that mediates most of the endogenous nitric oxide (NO) synthesis in the blood vessels. Endogenous NO is not only a regulating factor of the vascular tone, but also participates in modulating the proliferation and migration of endothelial cells, vascular remodeling, and angiogenesis process (3).
Sp1 is the one of the representative members of the zinc finger protein family, which binds to DNA via three conserved zinc finger structures, plays important regulatory roles in the expression of many genes. Interestingly, the GC box of the eNOS core promoter region contains sites with high affinity for Sp1, and Sp1 is an essential transcription factor for eNOS. Our previous studies suggest that the regulating effects of miR-24 on the endothelial cell proliferation and its inhibiting effects on eNOS are related to the expression of Sp1 (4). However, whether the inhibiting effects of miR-24 on the expression of eNOS are involved in the regulation of angiogenesis is still unclear.
In this study, the molecular mechanisms underlying the regulation of miR-24 on the expression of eNOS and Sp1 were investigated. Its effects on the proliferation and migration of endothelial cells and the luminal formation were also analyzed. Human umbilical vein endothelial cells (HUVECs) were used as in vitro models, and the high expression plasmids of miR-24 and its antisense sequences were constructed. The plasmids were transfected into the HUVECs, and the cell proliferation and migration, as well as the angiogenesis, were evaluated. The expression levels of eNOS and Sp1 were detected.
To investigate the effects of miR-24 on the proliferation of HUVECs, the MTT assay was performed. Our results showed that, the cell proliferation was significantly inhibited in the miR-24 high expression group. After 72-h-culture, compared with the control group, the OD value in the miR-24 high expression group was declined by 46.84% (0.42 ± 0.01 vs. 0.79 ± 0.03; P < 0.01), while the OD value in the miR-24 interference group (0.57 ± 0.02) was significantly declined by 27.85% (P < 0.01). The OD value in the miR-24 interference group was 35.71% higher than the miR-24 high expression groups (P < 0.01) (Fig. 1). These results suggest that miR-24 might inhibit the proliferation of HUVECs in vitro.
To investigate the effects of miR-24 on the migration ability of HUVECs, the Scratch assay and the Transwell chamber assay were performed. Our results from the Scratch assay showed that, at 24 h after scratching, compared with the control group, the migration rate of HUVECs in the miR-24 high expression group was significantly decreased by 55.56% (0.32 ± 0.01 vs. 0.72 ± 0.01; P < 0.01), while the migration rate in the miR-24 interference group (0.51 ± 0.02) was declined by 29.17% (P < 0.01). Compared with the miR-24 high expression group, the migration rate in the miR-24 interference group was increased by 59.38% (P < 0.01) (Fig. 2A).
On the other hand, our results from the Transwell chamber assay showed that, compared with the control group, the migrating cells in the miR-24 high expression group were significantly decreased by 61.20% (160.00 ± 4.24 vs. 412.40 ± 5.85; P < 0.01), while the cell number in the miR-24 interference group (269.00 ± 4.00) was significantly decreased by 34.77% (P < 0.01). Compared with the miR-24 high expression group, the migrating cell number in the miR-24 interference group was significantly increased by 68.13% (P < 0.01) (Fig. 2B). Taken together, these results suggest that miR-24 could, to some extent, inhibit the migration ability of HUVECs.
The proliferation and migration abilities of HUVECs are closely linked with the tube formation process. In investigate the effects of miR-24 on the tube formation ability of HUVECs, the Matrigel assay was performed. Our results showed that, compared with the control group, the tube number, length, and width were relatively decreased in the miR-24 interference group. However, in the miR-24 high expression group, the HUVECs were prone to aggregate, even though no tube-like network structure was formed (Fig. 3). These results suggest that, miR-24 might inhibit the tube formation ability of HUVECs.
To investigate the effects of miR-24 on the expression levels of eNOS and Sp1 in HUVECs, RT-PCR and Western blot analysis were performed. Our results from the RT-PCR showed that, compared with the control group, the mRNA expression level of eNOS in the miR-24 high expression group was significantly declined by 44.44% (0.45 ± 0.03 vs. 0.81 ± 0.01; P < 0.01), while the eNOS mRNA level in the miR-24 interference group (0.65 ± 0.02) was declined by 19.75% (P < 0.01). Compared with the miR-24 high expression group, the eNOS mRNA expression level in the miR-24 interference group was increased by 44.44% (P < 0.01). For the Sp1, compared with the control group, the mRNA expression level of Sp1 in the miR-24 high expression group was significantly declined by 34.88% (0.56 ± 0. 02 vs. 0. 86 ± 0.02; P < 0.01), while the Sp1 mRNA level in the miR-24 interference group (0.73 ± 0.02) was declined by 15.12% (P < 0.01). Compared with the miR-24 high expression group, the Sp1 mRNA expression level in the miR-24 interference group was increased by 30.36% (P < 0.01) (Fig. 4).
Similar results were obtained from the Western blot analysis. Our results showed that, compared with the control group, the protein expression level of eNOS in the miR-24 high expression group was significantly declined by 47.00% (0.53 ± 0.01 vs. 1.00 ± 0.02; P < 0.01), while the eNOS protein level in the miR-24 interference group (0.73 ± 0.02) was declined by 27.00% (P < 0.01). Compared with the miR-24 high expression group, the eNOS protein expression level in the miR-24 interference group was increased by 37.74% (P < 0.01). For the Sp1, compared with the control group, the protein expression level of Sp1 in the miR-24 high expression group was significantly down-regulated by 68.00% (0.32 ± 0.02 vs. 1.00 ± 0.03; P < 0.01), while the Sp1 protein level in the miR-24 interference group (0.58 ± 0.03) was declined by 42.00% (P < 0.01). Compared with the miR-24 high expression group, the Sp1 mRNA expression level in the miR-24 interference group was increased by 81.25% (P < 0.01) (Fig. 4). Taken together, these results suggest that, miR-24 could significantly down-regulated the expression of eNOS and Sp1 in the HUVECs, on both the mRNA and protein levels.
In present study, our results showed that miR-24 significantly inhibited the expression levels of eNOS and the transcription factor of Sp1 in the HUVECs. Together with miR-24, Sp1 (as an important regulatory factor) participated in the regulation of eNOS expression. Moreover, the regulatory mechanisms may be related to the inhibiting effects of miR-24 on the tube formation ability of HUVECs. Furthermore, our results showed that miR-24 might inhibit the proliferation of HUVECs. These results suggest that miR-24 might regulate the angiogenesis by regulating the endothelial cell proliferation and tube formation.
Angiogenesis refers to the process concerning the formation of new blood vessels from the original blood vessels, which not only occurs throughout the entire life process, but also play an important role in the pathogenesis of cardiovascular diseases. Recent studies have shown that angiogenesis is closely related to the regulating effects of certain miRNAs. For example, maturation of interfering miRNAs in the endothelial cells would affect the endothelial cell function and angiogenesis ability. Moreover, in the rat models, knock-out of the Dicer gene during gestation might cause abnormal angiogenesis and even embryo death.
MiR-24 belongs to the miR-23-27-24 family, with the highest expression in the heart, especially in the vascular tissues (5). It is noteworthy that 16 miRNAs are significantly down-regulated in the plasma of hypertensive patients, while 14 miRNAs (including miR-24) are significantly up-regulated. Moreover, miR-24 is positively correlated with the severity and complications of hypertension. However, although significant progress has been made in investigating the regulatory role of miR-24 in the cardiomyocyte apoptosis during the course of myocardial infarction, and the corresponding signaling pathways and biological effects have been gradually elucidated, study of the promoting effects of miR-24 on angiogenesis via regulating endothelial cells is still in its infancy.
The eNOS is a tissue-specific gene, and its product NO is not only a relaxing factor that regulates the vascular tone, but also plays a crucial role in the endothelial cell proliferation and migration, as well as in the vascular remodeling and angiogenesis (3). However, along with the increasing age or the pathological process, the reduced NO production due to endothelial cell dysfunction would lead to weakened angiogenesis, and the reduced repairing capacity of the damaged vascular endothelium. For example, NO production is reduced in patients with heart failure, with reduced circulating endothelial progenitor cells and declined activity. It has been widely recognized that stimulating endothelial cell migration promotes the repairing of vascular endothelium and the formation of capillaries, which might contribute to the treatment of cardiovascular diseases. At present, stem cell transplantation therapy is a novel and promising treatment option for the ischemic heart disease in clinic (6). Recent in vitro experiments have confirmed that the expression of eNOS is closely related to the migration ability of MSCs (7). Further studies suggest that the zinc finger proteins can promote the differentiating direction of the endothelial progenitor cells into the endothelial cells, via enhancing the expression level of eNOS.
Sp1 is the one of the representative members of the zinc finger protein family. The GC box in the eNOS core promoter region contains sites with high affinity for Sp1, and Sp1 is an essential transcription factor for eNOS. Strikingly, miR-24 could promote the directed differentiation of stem cells and the functions of cardiovascular progenitor cells (CPC). MiR-24 could improve the survival rate of CPC after transplanted into the cardiac MI region (8), which promotes the aggregation of these stem cells onto the vascular wall through the chemotaxis effects, making the blood vessels stable and mature. However, further in-depth studies are still needed to elucidate the underlying mechanism.
In conclusion, our results showed that miR-24 inhibited the proliferation, migration, and tube formation abilities of HUVECs, by regulating the expression levels of eNOS and Sp1. However, the regulatory effects of miR-24 on angiogenesis, and whether it participates in the differentiation of stem cells into endothelial cells, remain to be further explored in the future.
The miR-24 sequence was obtained from the http://www.miRbase.org website, which was 5’-UGGCUCAGUUCAGCAGGAACAG-3’. The anti-miRNA-24 was used to down-regulate miR-24 and interfere with its action, and the sequence was complementary to miR-24, i.e., 5’-ACCGAGUCAAGUCGUCCUUGUC-3’. The control sequence was as follows: 5’-GUCAUCAGUCGAGCUAGACGAG-3’. First-strand DNA was obtained, as well as the corresponding double-stranded DNA. After amplification through PCR, the in vitro recombination was performed, and the fragments were inserted into the pEGP-miR vectors (Cell Biolabs, San Diego, CA, USA). The following vectors were obtained: the pEGP-miRNA-24, pEGP-anti-miRNA-24, and pEGP-control vectors. These vectors were transformed into competent E.coli DH5α host strains, which were cultured on the ampicillin-resistant plates. The correct monoclonal colonies were picked, and after shaking, the plasmid DNA was obtained and subjected to the DNA sequencing (Sangon Biotech, Shanghai, China).
HUVECs were provided from Procell, Wuhan, Hubei, China. These cells were cultured with the 1640 medium (Gibco, Mt Waverley, Australia), containing 1 × 105 U/L penicillin and 100 mg/L streptomycin, and 10% fetal bovine serum (FBS; Gibco), in a 37 °C, 5% CO2 humidified incubator. For the cell transfection, the extracted plasmid concentrations were measured using a NANO nucleic acid analyzer. Then the plasmid was diluted with serum-free 1640 medium to the concentration of 0.01 µg/µL, which was mixed with the X-treme GENE HP DNA transfection agent (with the ratio of 1 µg: 3 µL; Roche Diagnostics, Mannheim, Germany). The normal HUVECs were cultured with the mixture medium for 24 h, which was replaced by the 1640 medium containing 10% FBS, and the fluorescence was detected. These cells were divided into the following groups: the miR-24 high expression, miR-24 interference (anti-miR-24), and blank control groups.
Proliferation of HUVECs was detected by the MTT assay (Solec Technology Co., Ltd., Beijing, China), according to the previously described method (9). Cells were planted onto the 96-well plate, at the density of 5 × 103 /well. When 50% confluence was reached, the cells were cultured with serum-free medium for 24 h. At 24 h, 48 h, and 72 h after transfection, 10 µL MTT was added into each well to incubate the cells for further 4 h. Then the medium was discarded, and 100 µL DMSO was added into each well. After shaking for 15 s, the absorbance at 570 nm (OD570 nm) was detected on a fluorescence detector. Experiments were performed in triplicates.
Migration abilities of HUVECs were detected by the Scratch assay and Transwell chamber assay. For the Scratch assay (10), the cells were planted onto the 6-well plate, at the density of 4 × 105/well. After adherence, a short line was marked on the bottom of the plate with the pipette tip. Then the cells were washed with PBS (pH 7.4), and then cultured with serum-free 1640 medium. At 0 h and 24 h after this, the migration status was observed, and the short line width was measured. The migration ratio was calculated as follows: Migration ratio = (line width at 0 h - line width at 24 h) / line width at 0 h.
On the other hand, the migration ability of HUVECs was also detected by the Transwell chamber assay (3). The cells were planted on the upper chamber in the Transwell plate, at the density of 1 × 104/well, and cultured with serum-free 1640 medium. The lower chamber was added with 500 µL medium containing serum. After 12 h, the upper chamber was removed. The cells were carefully wiped off with a cotton swab, and fixed with 4% paraformaldehyde for 15 min. The upper chamber was washed with PBS, and stained with crystal violet at room temperature for 1 h. The cells in the lower chamber were observed with the inverted microscope. The five fields were randomly selected, and the cells were counted.
Tube formation capacity of HUVECs was examined by the Matrigel assay (Corning, Corning, NY, USA) (3). The 96-well plates were pre-coated with Matrigel (20 µL each well) on ice. Then the plated was placed in the 37 °C, 5% CO2 incubator for 1 h. The cells were seeded onto the Matrigel-coated plates, at the density of 1 × 104/well, and incubated for 12 h. Then five fields were randomly selected, and the small tubes were observed under microscope.
Total RNA was extracted with TRIzol. The first-strand DNA was synthesized with the following system: 4 µL 5 × reaction buffer, 1 µL RiboLock™ Ribonuclease Inhibitor (20 U/µL), 2 µL 10 mmol/L dNTP Mix, at 37 °C for 5 min, followed by adding 1 µL reverse transcriptase, at 42 °C for 1 h, and at 70 °C for 10 min. RT-PCR was performed with the PCR Kit from Tiangen Biotech, Beijing, China. The primer sequences were as follows: eNOS, forward 5’-AGGAACCTGTGTGACCCTCA-3’ and reverse 5’-CGAGGTGGTCCGGGTATCC-3’; Sp1, forward 5’-AGGTGCACCAGCTTCCAGGCCTG-3’ and reverse 5’-CCAGGTCCATGAAGGCCAAGTTG-3’; and β-actin, forward 5’-CTGGAACGGTGAAGGTGACA-3’ and reverse 5’-AAGGGACTTCCTGTAACAATGCA-3’. The PCR conditions were as follows: 94 °C for 5 min; 94 °C for 30 s, 56 °C for 1 min, 72 °C for 1 min, for totally 30 cycles; followed by 72 °C for 5 min. Totally 5 µL PCR products were subjected to the 1.5% agarose gel electrophoresis analysis.
Cell protein was lysed with lysis. The protein concentration was determined, and 30 µg protein was subjected to 8% SDS-PAGE, which was then electronically transferred onto the PVDF membrane. After blocking with non-fat milk for 1 h, the membrane was incubated with rabbit anti-human anti-eNOS primary polyclonal antibody (1:1000 dilution; Abcam, Cambridge, MA, UK) and rabbit anti-human anti-Sp1 primary polyclonal antibody (1:1000 dilution; Abcam), respectively, at 4 °C overnight. After washing with TBST (0.14 mol/L NaCl, 2.7 mmol/L KCl, 24.8 mmol/L Trise base, and 1% Tween; pH = 7.4). Then the membrane was incubated by the horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:2000 dilution; Santa Cruz, Santa Cruz, CA, USA), at room temperature for 1 h. The protein bands were scanned and analyzed by the Odyssey infrared fluorescence imaging system (Li-Cor Inc., Lincoln, NE, USA).
Data were expressed as mean ± SD. SPSS 16.0 software was used for statistical analysis. One-way ANOVA was performed for the group comparison, with the LSD-t and SNK-q tests. P < 0.05 was considered statistically significant.
cardiovascular progenitor cells
Endothelial nitric oxide synthase
Human umbilical vein endothelial cells
nitric oxide
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data and materials
The data that support the findings of this study are available on request from the corresponding author.
Competing interests
The authors declare that they have no competing interests.
Funding
This work was supported by the National Natural Science Foundation of China (81373403), and the Guangxi Postgraduate Research Innovation Project (YCSZ2015119). The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Authors' contributions
WC performed the experiments, acquired data and wrote manuscript. XL contributed reagents, materials and analysis tools. NG performed the experiments. YQ analyzed the data. ZL, DL searched literatures and revised manuscript. HO designed the research, collected funds and wrote manuscript. All authors read and approved the final manuscript.
Acknowledgements
Not applicable.